"Prymula, Roman" . . "Z(MO0FVZ0000502)" . . . "RIV/60162694:G44__/08:00002038" . . . "4"^^ . . "1"^^ . "2" . "Posp\u00ED\u0161ilov\u00E1, K." . . . . . . "2"^^ . "CZ - \u010Cesk\u00E1 republika" . . . . "Current strategy to pneumococcal conjugate vaccine immunization"@en . "Streptococcus pneumoniae causes di versiform scale of various diseases in childhood ranging from the most serious invasive like meningitis and septicemias (bacteriemias) through pneumonias up to life as a rule not threatening but all the more frequent acute otitis and sinusitis. Incidence of invasive pneumococcal diseases varies in different countries.Either the mass immunization strategy or risk group strategy are applied in the EU in current situation.However the risk group strat\u00E9gy is only an interlink in transition to the mass strategy.Among the mass European strategies schedules 2+1 or 3+1 are put on.The disadvantage of 2+1 strategy are regrettably in some degree lower antibody levels in s\u00E9rotypes 6B a 23F,which massively appear in the Czech Republic and introduction of this schedule could limit its effectiveness.Administration of single or two-dose regimens,which are economically profitable,however they do not cover the major risks in categories of youngest kids, is not taken into consideration"@en . "G44" . "88" . "Pneumococci; invasive pneumococcal diseases; acute otits media; pneumococcal conjugate vaccine; immunogenicity; reactogenicity; mass immuzation"@en . . "RIV/60162694:G44__/08:00002038!RIV09-MO0-G44_____" . "0032-6739" . "[B73730A6E498]" . . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k o\u010Dkov\u00E1n\u00ED konjugovanou pneumokokovou vakc\u00EDnou" . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k o\u010Dkov\u00E1n\u00ED konjugovanou pneumokokovou vakc\u00EDnou" . "Streptococcus pneumoniae zp\u016Fsobuje v d\u011Btsk\u00E9m v\u011Bku pestrou \u0161k\u00E1lu r\u016Fzn\u00FDch onemocn\u011Bn\u00ED. Od nejz\u00E1va\u017En\u011Bj\u0161\u00EDch invaz\u00EDvn\u00EDch, jako jsou meningit\u00EDdy a septik\u00E9mie (bakteriemie), p\u0159es pneumonie a\u017E po \u017Eivot zpravidla neohro\u017Euj\u00EDc\u00ED, av\u0161ak o to \u010Detn\u011Bj\u0161\u00ED akutn\u00ED otitidy a sinusitidy. Incidence invaz\u00EDvn\u00EDch pneumokokov\u00FDch onemocn\u011Bn\u00ED se v r\u016Fzn\u00FDch zem\u00EDch li\u0161\u00ED. V st\u00E1vaj\u00EDc\u00ED situaci je aplikov\u00E1na v EU bu\u010F plo\u0161n\u00E1 strategie, nebo o\u010Dkov\u00E1n\u00ED rizikov\u00FDch skupin. O\u010Dkov\u00E1n\u00ED rizikov\u00FDch skupin je v\u0161ak pouze mezi\u010Dl\u00E1nkem v p\u0159echodu na plo\u0161nou strategii. V plo\u0161n\u00FDch Evropsk\u00FDch strategi\u00EDch se uplat\u0148uj\u00ED sch\u00E9mata 2+1 nebo 3+1. Nev\u00FDhodou sch\u00E9matu 2+1 je bohu\u017Eel pon\u011Bkud ni\u017E\u0161\u00ED hladina protil\u00E1tek u s\u00E9rotyp\u016F 6B a 23F, kter\u00E9 se v \u010CR masivn\u011B vyskytuj\u00ED, a zaveden\u00ED tohoto sch\u00E9matu by mohlo \u00FA\u010Dinnost o\u010Dkov\u00E1n\u00ED limitovat. U pneumokokov\u00FDch onemocn\u011Bn\u00ED se zat\u00EDm neuva\u017Euje o aplikaci jednod\u00E1vkov\u00FDch \u010Di dvoud\u00E1vkov\u00FDch sch\u00E9mat plo\u0161n\u011B jako u meningokok\u016F nad 1 rok v\u011Bku, kter\u00E1 jsou sice ekonomicky v\u00FDhodn\u00E1, ale hlavn\u00ED rizika v kategori\u00EDch nejmlad\u0161\u00EDch d\u011Bt\u00ED bohu\u017Eel nekryj\u00ED"@cs . . "Praktick\u00FD l\u00E9ka\u0159" . "Current strategy to pneumococcal conjugate vaccine immunization"@en . . "396082" . "Streptococcus pneumoniae zp\u016Fsobuje v d\u011Btsk\u00E9m v\u011Bku pestrou \u0161k\u00E1lu r\u016Fzn\u00FDch onemocn\u011Bn\u00ED. Od nejz\u00E1va\u017En\u011Bj\u0161\u00EDch invaz\u00EDvn\u00EDch, jako jsou meningit\u00EDdy a septik\u00E9mie (bakteriemie), p\u0159es pneumonie a\u017E po \u017Eivot zpravidla neohro\u017Euj\u00EDc\u00ED, av\u0161ak o to \u010Detn\u011Bj\u0161\u00ED akutn\u00ED otitidy a sinusitidy. Incidence invaz\u00EDvn\u00EDch pneumokokov\u00FDch onemocn\u011Bn\u00ED se v r\u016Fzn\u00FDch zem\u00EDch li\u0161\u00ED. V st\u00E1vaj\u00EDc\u00ED situaci je aplikov\u00E1na v EU bu\u010F plo\u0161n\u00E1 strategie, nebo o\u010Dkov\u00E1n\u00ED rizikov\u00FDch skupin. O\u010Dkov\u00E1n\u00ED rizikov\u00FDch skupin je v\u0161ak pouze mezi\u010Dl\u00E1nkem v p\u0159echodu na plo\u0161nou strategii. V plo\u0161n\u00FDch Evropsk\u00FDch strategi\u00EDch se uplat\u0148uj\u00ED sch\u00E9mata 2+1 nebo 3+1. Nev\u00FDhodou sch\u00E9matu 2+1 je bohu\u017Eel pon\u011Bkud ni\u017E\u0161\u00ED hladina protil\u00E1tek u s\u00E9rotyp\u016F 6B a 23F, kter\u00E9 se v \u010CR masivn\u011B vyskytuj\u00ED, a zaveden\u00ED tohoto sch\u00E9matu by mohlo \u00FA\u010Dinnost o\u010Dkov\u00E1n\u00ED limitovat. U pneumokokov\u00FDch onemocn\u011Bn\u00ED se zat\u00EDm neuva\u017Euje o aplikaci jednod\u00E1vkov\u00FDch \u010Di dvoud\u00E1vkov\u00FDch sch\u00E9mat plo\u0161n\u011B jako u meningokok\u016F nad 1 rok v\u011Bku, kter\u00E1 jsou sice ekonomicky v\u00FDhodn\u00E1, ale hlavn\u00ED rizika v kategori\u00EDch nejmlad\u0161\u00EDch d\u011Bt\u00ED bohu\u017Eel nekryj\u00ED" . . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k o\u010Dkov\u00E1n\u00ED konjugovanou pneumokokovou vakc\u00EDnou"@cs . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k o\u010Dkov\u00E1n\u00ED konjugovanou pneumokokovou vakc\u00EDnou"@cs .